Marker Therapeutics (MRKR) Times Interest Earned (2010 - 2026)

Marker Therapeutics (MRKR) posted quarterly Times Interest Earned of -$11.49 for Q1 2026, down 243.6% quarter-over-quarter from -$3.34 in Q4 2025.

Marker Therapeutics (MRKR) Times Interest Earned (2010 - 2026) Analysis & Trends

Marker Therapeutics (MRKR) has reported Times Interest Earned for 16 consecutive years, with -$11.49 the latest figure, recorded in Q1 2026.

In Q1 2026, Times Interest Earned changed N/A year-over-year to -$11.49; the TTM figure through Mar 2026 stood at -$34.86 (down 456.33% YoY), while the FY2025 annual figure was -$0.3, down 9.71% from the prior year.
Times Interest Earned retreated to -$11.49 in Q1 2026 per MRKR's latest filing, from -$3.34 in the prior quarter.
Across five years, Times Interest Earned topped out at -$0.36 in Q2 2022 and bottomed at -$387.37 in Q2 2025.
Historically, Times Interest Earned has averaged -$32.52 across 5 years, with a median of -$3.54 in 2024.
Annual changes were most pronounced in 2023 — Times Interest Earned surged 98.49% — and 2025, when it plunged 19939.11%.
Marker Therapeutics' Times Interest Earned stood at -$14.75 in 2022, then soared by 84.88% to -$2.23 in 2023, then tumbled by 358.32% to -$10.22 in 2024, then surged by 67.28% to -$3.34 in 2025, then sank by 243.6% to -$11.49 in 2026.
Business Quant data shows MRKR's Times Interest Earned at -$11.49 in Q1 2026, -$3.34 in Q4 2025, and -$387.37 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	117.59
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	8.18
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	2.82
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	76.86
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.08
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	1.42
10	Marker Therapeutics	27.04 Mn	15.11 Mn	-	-

Download Data